Conference
CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
Abstract
TPS5110
Authors
N. K; Saad F; Parulekar WR; Emmenegger U; Hotte SJ; Pouliot F; Bauman G; Zukotynski KA; Peacock S; Wyatt AW
Volume
40
Pagination
pp. tps5110-tps5110
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2022
DOI
10.1200/jco.2022.40.16_suppl.tps5110
Conference proceedings
Journal of Clinical Oncology
Issue
16_suppl
ISSN
0732-183X